Get the app
USHealthcare

Opko Health Inc (OPK)

US · Healthcare · Diagnostics & Research

$1.62+0.62%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$163.6M
Revenue YoY
+4.3%
Net profit
$-8.4M
EPS
$-0.01
EPS estimate
$-0.08
Net margin
-5.1%

EPS came in at -0.01 against a street estimate of -0.08 — a beat of 87.5%.

Key statistics

Market cap
$1.20B
Forward P/E
53.8
P/B
0.99
Book value
$1.59
EPS (TTM)
$-0.07
52-week high
$1.73
52-week low
$0.98
50-day MA
$1.40
200-day MA
$1.30
Beta
1.50

Analyst view

Analysts rate Opko Health Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $4.38.

Shareholding

Insiders
50.52%
Institutions
27.56%

Largest institutional holders

FundStake
Rubric Capital Management LP6.40%
BlackRock Inc4.85%
Vanguard Portfolio Management, LLC1.98%
Vanguard Capital Management, LLC1.94%
Geode Capital Management, LLC1.51%
State Street Corp1.27%
The Goldman Sachs Group Inc1.03%
UBS Group AG0.81%

Recent filings & reports

DocumentDate
Material agreement · Q3 2026
OPKO HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company issued $125,000,000 in additional senior secured notes on August 13, 2026 • Notes mature
2026-08-14
Quarterly report · Q2 2026
OPKO HEALTH, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Total Revenues (6 months ended June 30, 2026): $287.8 million vs. $306.8 million (2025
2026-07-27
Results announced · Q3 2026
OPKO HEALTH Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $163.5 million vs. $156.8 million in Q2 2025 (+4.3%) • Q2 2026 Net Lo
2026-07-27
Shareholder vote results · Q2 2026
OPKO HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 11 Board directors elected with strong approval margins • Tot
2026-06-18
Proxy statement · Q2 2026
OPKO HEALTH, INC. – PROXY SUMMARY FOR RETAIL INVESTORS CEO COMPENSATION • Phillip Frost, M.D. (CEO & Chairman): Total compensation figure not explic
2026-04-30
Quarterly report · Q1 2026
OPKO HEALTH, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total revenues (Q1 2026): $124.2 million vs. $150.0 million (Q1 2025) — decline of
2026-04-28
Results announced · Q2 2026
OPKO HEALTH Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Q1 2026 Revenue: $124.2 million vs. $149.9 million in Q1 2025 (down 17%) • Q1 2026 Ne
2026-04-28
Annual report FY2025
OPKO HEALTH, INC. – 2025 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal Year Ended: December 31, 2025 • Public Float (as of Q2 2025): $
2026-02-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Opko Health Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.